| First Published on Clinicaltrials.gov: |
5/6/2008 |
| Status: |
Ongoing, But Not Recruiting |
| ClinicalTrials.gov ID: |
NCT00673140 |
| Sponsor: |
GAAD Medical Research Institute Inc. |
| Purpose: |
This study will investigate the use of far infrared radiation for the control, management and treatment of ALS. |
| Phase: |
I |
| Treatment Type: |
Radiation: Far Infrared Radiation- 5μm to 20μm wavelength |
| Trial Type: |
Open Label |
| Estimated Enrollment: |
7 |
| Eligibility: |
Both genders. Not accepting healthy volunteers. |
| Details: |
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have ALS. |
| Collaborator(s): |
|
| Location(s): |
|
| Primary Investigator: |
Ken Nedd, M.D.- GAAD Medical Research Institute Inc. |
| Contact: |
|
| Trial Protocol as Published on Clinicaltrials.gov: |
|
| ALS Forum: |
|